Investor Relations
Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

Media Contact
Rooney & Associates
Terry Rooney
212-223-0689
trooney@rooneyco.com
or
Marion Janic
212-223-4017
mjanic@rooneyco.com

Press Releases

All Releases
View Summary Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Jun 3, 2008
PDF 11.8 KB
View Summary OPKO Health Acquires Company Developing Novel Glaucoma Therapy
May 7, 2008
PDF 11.7 KB
View Summary OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Mar 18, 2008
PDF 12.2 KB
View Summary OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
Feb 25, 2008
PDF 13.6 KB
View Summary OPKO Health Announces Changes to Board of Directors
Jan 25, 2008
PDF 11.0 KB
View Summary OPKO Health to Present at 2008 Wachovia Healthcare Conference
Jan 23, 2008
PDF 8.5 KB
View Summary OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
Jan 14, 2008
PDF 12.7 KB
View Summary OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Dec 6, 2007
PDF 11.7 KB
View Summary The Frost Group Invests $20 Million in OPKO Health
Dec 5, 2007
PDF 11.2 KB
View Summary OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc.
Nov 29, 2007
PDF 10.9 KB
View Summary OPKO Health Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections
Oct 30, 2007
PDF 11.5 KB
View Summary OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye
Oct 10, 2007
PDF 10.6 KB
View Summary OPKO Health Appoints Pascal J. Goldschmidt To Board Of Directors
Oct 1, 2007
PDF 9.7 KB
View Summary OPKO Health to Present at UBS 2007 Global Life Sciences Conference
Sep 18, 2007
PDF 9.6 KB
View Summary OPKO Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Aug 30, 2007
PDF 11.4 KB
View Summary OPKO Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost
Jul 12, 2007
PDF 7.4 KB
View Summary OPKO Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
Jul 11, 2007
PDF 10.4 KB
View Summary Exegenics Changes Name to OPKO Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Jun 8, 2007
PDF 4.1 KB
View Summary OPKO Health, Inc. to Acquire Diagnostic Imaging Firm
Jun 1, 2007
PDF 6.4 KB
View Summary Exegenics, Inc. Announces Senior Management Appointments; Company Intends to Change its Name to OPKO Health
May 4, 2007
PDF 9.2 KB
Showing 321-340 of 341 Page: 1 ... 13 14 15 16 17 18  Previous 20 | Next 20

Email  Sign up for email alerts